• US Preventive Services Task Force, Douglas K Owens, Karina W Davidson, Alex H Krist, Michael J Barry, Michael Cabana, Aaron B Caughey, Katrina Donahue, Chyke A Doubeni, John W Epling, Martha Kubik, Gbenga Ogedegbe, Lori Pbert, Michael Silverstein, Melissa A Simon, Chien-Wen Tseng, and John B Wong.
• Veterans Affairs Palo Alto Health Care System, Palo Alto, California.
• JAMA. 2020 Mar 10; 323 (10): 970-975.

ImportanceHepatitis C virus (HCV) is the most common chronic blood-borne pathogen in the US and a leading cause of complications from chronic liver disease. HCV is associated with more deaths than the top 60 other reportable infectious diseases combined, including HIV. Cases of acute HCV infection have increased approximately 3.8-fold over the last decade because of increasing injection drug use and improved surveillance.ObjectiveTo update its 2013 recommendation, the USPSTF commissioned a review of the evidence on screening for HCV infection in adolescents and adults.PopulationThis recommendation applies to all asymptomatic adults aged 18 to 79 years without known liver disease.Evidence AssessmentThe USPSTF concludes with moderate certainty that screening for HCV infection in adults aged 18 to 79 years has substantial net benefit.RecommendationThe USPSTF recommends screening for HCV infection in adults aged 18 to 79 years. (B recommendation).

24 keywords...

hide…